EMZAHH Drug Patent Profile
✉ Email this page to a colleague
When do Emzahh patents expire, and when can generic versions of Emzahh launch?
Emzahh is a drug marketed by Aurobindo Pharma and is included in one NDA.
The generic ingredient in EMZAHH is norethindrone. There are twenty-six drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the norethindrone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Emzahh
A generic version of EMZAHH was approved as norethindrone by GLENMARK PHARMS LTD on July 22nd, 2010.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for EMZAHH?
- What are the global sales for EMZAHH?
- What is Average Wholesale Price for EMZAHH?
Summary for EMZAHH
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Drug Prices: | Drug price information for EMZAHH |
| DailyMed Link: | EMZAHH at DailyMed |
Pharmacology for EMZAHH
| Drug Class | Progestin |
US Patents and Regulatory Information for EMZAHH
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aurobindo Pharma | EMZAHH | norethindrone | TABLET;ORAL-28 | 216796-001 | Jan 6, 2023 | AB2 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
